AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Scope & Guideline

Innovating the future of respiratory physiology.

Introduction

Welcome to the AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1040-0605
PublisherAMER PHYSIOLOGICAL SOC
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1989 to 2024
AbbreviationAM J PHYSIOL-LUNG C / Am. J. Physiol.-Lung Cell. Mol. Physiol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address6120 Executive Blvd, Suite 600, Rockville, MD 20852, UNITED STATES

Aims and Scopes

The American Journal of Physiology-Lung Cellular and Molecular Physiology focuses on advancing the understanding of lung biology through a multidisciplinary approach that encompasses cellular and molecular physiology, pathophysiology, and therapeutic interventions. The journal emphasizes research that elucidates mechanisms underlying lung diseases and promotes knowledge that can lead to innovative treatments.
  1. Lung Cellular and Molecular Physiology:
    The journal publishes studies that investigate the fundamental cellular and molecular processes in lung physiology, including cellular signaling pathways, gene expression, and the role of various cell types in maintaining lung function.
  2. Pathophysiology of Lung Diseases:
    Research addressing the pathological mechanisms of lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and acute respiratory distress syndrome (ARDS) is a core focus, providing insights into disease mechanisms and potential therapeutic targets.
  3. Respiratory Inflammation and Immunity:
    The journal covers research on the immune responses in the lung, including inflammation, immune cell interactions, and the effects of environmental factors such as allergens and pollutants on lung health.
  4. Innovative Therapeutic Approaches:
    Research on novel therapeutic strategies, including stem cell therapies, bioengineering, and pharmacological interventions aimed at treating lung diseases, is a significant area of interest.
  5. Translational Research:
    The journal emphasizes studies that bridge basic research and clinical applications, aiming to translate findings from the laboratory to the bedside to improve patient outcomes in lung health.
The American Journal of Physiology-Lung Cellular and Molecular Physiology has seen the emergence of several trending themes in recent publications, reflecting the dynamic nature of research in lung physiology and pathology. These themes highlight the journal’s commitment to addressing current challenges and innovations in the field.
  1. Impact of COVID-19 on Lung Health:
    There is a significant increase in research focusing on the effects of COVID-19 on lung physiology and pathology, including studies on acute lung injury, long-term pulmonary sequelae, and the interplay between COVID-19 and preexisting lung conditions.
  2. Role of Extracellular Vesicles:
    Research on the role of extracellular vesicles in lung health and disease is gaining traction, highlighting their potential as biomarkers and therapeutic targets in conditions such as COPD and pulmonary fibrosis.
  3. Sex Differences in Lung Disease:
    An emerging theme is the exploration of sex differences in lung physiology and disease response, recognizing the need to understand how biological sex influences lung health outcomes.
  4. Environmental and Lifestyle Factors:
    There is a growing emphasis on the impact of environmental exposures, such as pollution and e-cigarette use, on lung health, reflecting a broader interest in how lifestyle choices affect respiratory diseases.
  5. Stem Cell and Regenerative Medicine Approaches:
    Innovations in stem cell research and regenerative medicine aimed at repairing lung tissue and restoring function are increasingly featured, indicating a shift towards potential curative therapies.

Declining or Waning

While the journal maintains a robust focus on various aspects of lung physiology and pathology, certain themes appear to be declining in prominence based on recent publications. This shift may reflect evolving research priorities and emerging areas of interest.
  1. Basic Animal Models:
    There has been a noticeable decrease in studies utilizing basic animal models for lung research, as the field increasingly emphasizes translational research that directly relates to human health and disease.
  2. Non-invasive Techniques:
    Research employing traditional non-invasive measurement techniques for lung function and pathology seems to be waning, potentially replaced by advanced imaging and molecular techniques that offer higher resolution and specificity.
  3. Historical Perspectives on Lung Diseases:
    Papers focusing on historical perspectives or reviews of past research trends in lung diseases appear to be less frequent, indicating a shift towards more contemporary and forward-looking studies.

Similar Journals

PULMONARY PHARMACOLOGY & THERAPEUTICS

Elevating standards in pulmonary pharmacology and therapy.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1094-5539Frequency: 6 issues/year

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

BMC Pulmonary Medicine

Fostering collaboration and knowledge in respiratory care.
Publisher: BMCISSN: 1471-2466Frequency: 1 issue/year

BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.

THORAX

Connecting researchers and clinicians for better lung health.
Publisher: BMJ PUBLISHING GROUPISSN: 0040-6376Frequency: 12 issues/year

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

CHEST

Elevating the standards of pulmonary medicine research.
Publisher: ELSEVIERISSN: 0012-3692Frequency: 12 issues/year

CHEST is a premier journal published by Elsevier, focusing on the vital fields of cardiology, critical care, and pulmonary medicine. Established in 1970, this esteemed journal has continually provided authoritative research, reviews, and clinical studies, catering to a global audience of healthcare professionals, researchers, and students. With an impressive impact factor, CHEST ranks in the top quartile (Q1) across its core categories according to the latest Scopus metrics, securing its position as a leading resource within cardiology (Rank #16), pulmonary (Rank #9), and critical care (Rank #8). Published quarterly, it offers a wealth of knowledge essential for advancing understanding and improving patient outcomes in these critical areas of healthcare. Researchers and practitioners are encouraged to submit their work, contributing to the ongoing discourse that shapes innovative practices and policies in respiratory and cardiovascular health.

RESPIRATORY RESEARCH

Pioneering Insights for a Breath of Fresh Air
Publisher: BMCISSN: Frequency: 1 issue/year

RESPIRATORY RESEARCH is a leading open-access journal published by BMC, dedicated to advancing the field of pulmonary and respiratory medicine. Since its inception in 2000, this journal has provided a vital platform for disseminating high-quality research, covering a broad spectrum of topics from basic science to innovative clinical practices in respiratory health. With an impressive impact factor and a Q1 ranking in the Pulmonary and Respiratory Medicine category, RESPIRATORY RESEARCH is recognized for its significant contribution to the literature, currently positioned at rank #19 out of 155 in the Scopus database, highlighting its relevance and influence within the medical community. The journal’s commitment to open access ensures that all articles are freely available to researchers, professionals, and students, fostering collaboration and knowledge sharing in the field. With its convergence years spanning from 2000 to 2024, RESPIRATORY RESEARCH remains at the forefront of respiratory medicine research, making it an essential resource for all stakeholders in this vital medical domain.

Tuberculosis and Respiratory Diseases

Championing open access for global health insights.
Publisher: THE KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASESISSN: 1738-3536Frequency: 4 issues/year

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

Zeitschrift fur Pneumologie

Bridging Research and Practice in Respiratory Medicine
Publisher: SPRINGER HEIDELBERGISSN: 2731-7404Frequency: 6 issues/year

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

Pulmonary Circulation

Championing open access to vital pulmonary research.
Publisher: WILEYISSN: 2045-8932Frequency: 4 issues/year

Pulmonary Circulation is a leading open-access journal published by Wiley, focused on advancing the field of pulmonary and respiratory medicine. Established in 2011, the journal has garnered a prestigious reputation, achieving a Q2 ranking in 2023 among its category and ranking #70 out of 155 in Scopus within the specialty of Medicine – Pulmonary and Respiratory Medicine, reflecting its growing influence and relevance in the scientific community. With its commitment to delivering high-quality, peer-reviewed research, Pulmonary Circulation serves as a vital resource for researchers, clinicians, and students seeking to explore innovative ideas and findings in lung health, pulmonary vascular diseases, and therapeutic approaches. The journal has been open access since 2017, ensuring that groundbreaking research is accessible to a wider audience, thus promoting collaboration and knowledge exchange in this dynamic field. Located in the heart of the United States at 111 River St, Hoboken, NJ 07030-5774, the journal is dedicated to fostering advancements in pulmonary health and addressing real-world challenges facing patients globally.

HEART & LUNG

Exploring the Frontiers of Cardiovascular and Respiratory Medicine
Publisher: MOSBY-ELSEVIERISSN: 0147-9563Frequency: 6 issues/year

HEART & LUNG is a premier academic journal published by MOSBY-ELSEVIER, focusing on the critical intersections of cardiology, critical care, and respiratory medicine. Since its inception in 1973, the journal has established a significant reputation within the medical community, as evidenced by its impressive Q2 ranking in key categories such as Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, and Pulmonary and Respiratory Medicine for the year 2023. With a dedicated readership comprising researchers, healthcare professionals, and students, HEART & LUNG serves as a vital platform for disseminating cutting-edge research, clinical innovations, and comprehensive reviews that influence practice standards and enhance patient care. While it currently does not offer Open Access options, readers can access a wealth of information pivotal to the advancement of medical knowledge and practice through conventional subscription. Explore the latest findings and contribute to the ever-evolving landscape of cardiovascular and respiratory health through this esteemed journal.

LUNG

Innovating the future of pulmonary medicine with every publication.
Publisher: SPRINGERISSN: 0341-2040Frequency: 6 issues/year

LUNG is a prestigious academic journal that has been a cornerstone in the field of Pulmonary and Respiratory Medicine since its inception in 1959. Published by SPRINGER, the journal holds an impressive Q1 ranking in its category for 2023, reflecting its commitment to disseminating high-quality research and advancing clinical practices in respiratory health. With a Scopus rank of 24 out of 155 in its field, representing the top 16% of journals, LUNG continues to serve as a vital platform for researchers, clinicians, and students who are dedicated to addressing the complexities of lung diseases. Although currently not an open-access journal, LUNG offers valuable insights and significant contributions to the understanding of respiratory conditions, ensuring that its readership stays at the forefront of medical advancements. Researchers and professionals are encouraged to submit their work and engage with a thriving academic community that is passionate about improving patient outcomes in pulmonary health.